Literature DB >> 7399708

Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition.

O Kohashi, A Tanaka, S Kotani, T Shiba, S Kusumoto, K Yokogawa, S Kawata, A Ozawa.   

Abstract

A synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), failed to produce polyarthritis with a wide dose range in a water-in-oil emulsion of mineral oil such as liquid paraffin, Drakeol, or heavy mineral oil. MDP, however, produced moderate to severe arthritis with almost 100% incidence in a water-in-oil emulsion made up of Difco incomplete adjuvant, which consists of Bavol F as an oil vehicle and Arlacel A as an emulsifier. N-acetylmuramyl-L-alanyl-L-isoglutamine did not produce arthritis, whereas 4,6-diacetyl-MDP produced the disease. Bacterial peptidoglycans, such as disaccharide peptides which were N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine and N-acetylglucosaminyl-6,o-acetyl-N-acetylmuramyl-L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine, also produced polyarthritis with low incidence in Difco oil but not in the other mineral oils described above. MDP and bacterial disaccharide peptides were able to produce the disease even in the latter mineral oil only when the concentration of Arlacel A was increased from 15% to 20 to 30% in the oil. We concluded that one of the minimal essential structures responsible for development of this disease is MDP, although the role of the oil vehicle remained uncertain, and there is no direct correlation between granulona formation and arthritogenicity of MDP.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7399708      PMCID: PMC551076          DOI: 10.1128/iai.29.1.70-75.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Development of arthritis, periarthritis and periostitis in rats given adjuvants.

Authors:  C M PEARSON
Journal:  Proc Soc Exp Biol Med       Date:  1956-01

2.  Adjuvant polyarthritis. III. Evidence in support of viral etiology.

Authors:  Y H Chang; W Hoffman
Journal:  Arthritis Rheum       Date:  1977 Nov-Dec

3.  Dose-response hyperplasia and neoplasia from feeding N-2-fluorenylacetamide (2-FAA) to BALB/c mice for varying time intervals.

Authors:  T J Haley; J Farmer; W E Jaques; C Frith; R W Sprowls; G Schieferstein
Journal:  Proc Soc Exp Biol Med       Date:  1976-06

Review 4.  Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.

Authors:  L Chedid; F Audibert; A G Johnson
Journal:  Prog Allergy       Date:  1978

5.  Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition.

Authors:  M W Whitehouse; K J Orr; F W Beck; C M Pearson
Journal:  Immunology       Date:  1974-08       Impact factor: 7.397

6.  Structural requirements for arthritogenicity of peptidoglycans from Staphylococcus aureus and Lactobacillus plant arum and analogous synthetic compounds.

Authors:  O Kohashi; C M Pearson; Y Watanabe; S Kotani; T Koga
Journal:  J Immunol       Date:  1976-06       Impact factor: 5.422

7.  Preparation of various fractions from Mycobacterium smegmatis, their arthritogenicity and their preventive effect on adjuvant disease.

Authors:  O Kohashi; C M Pearson; T Shimono; S Kotani
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

8.  A comparison of n-hexadecane and mineral oil emulsions in induction of hypersensitivity in mice.

Authors:  A J Crowle; C C Hu
Journal:  Proc Soc Exp Biol Med       Date:  1966-10

9.  The adjuvant activity of a non-toxic, water-soluble glycopeptide present in large quantities in the culture filtrate of Mycobacterium tuberculosis strain DT.

Authors:  D E Stewart-Tull; T Shimono; S Kotani; M Kato; Y Ogawa; Y Yamamura; T Koga; C M Pearson
Journal:  Immunology       Date:  1975-07       Impact factor: 7.397

10.  Granuloma formation by synthetic bacterial cell wall fragment: muramyl dipeptide.

Authors:  K Emori; A Tanaka
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

View more
  16 in total

1.  The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes.

Authors:  B C Holm; L Svelander; A Bucht; J C Lorentzen
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats.

Authors:  B C Carlson; A M Jansson; A Larsson; A Bucht; J C Lorentzen
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  Arthropathic properties of gonococcal peptidoglycan fragments: implications for the pathogenesis of disseminated gonococcal disease.

Authors:  T J Fleming; D E Wallsmith; R S Rosenthal
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs.

Authors:  N E Byars
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Arthritogenic activity of a synthetic immunoadjuvant, muramyl dipeptide.

Authors:  Z Zídek; K Maśek; Z Jiricka
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

6.  Epithelioid granuloma induced by muramyl dipeptide in immunologically deficient rats.

Authors:  S Nagao; F Ota; K Emori; K Inoue; A Tanaka
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

7.  Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.

Authors:  M F Powell; L C Foster; A R Becker; W Lee
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

8.  Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.

Authors:  P Hambleton; S McMahon
Journal:  Agents Actions       Date:  1990-03

9.  Anti-inflammatory effects of muramyl dipeptide in experimental models of acute inflammation.

Authors:  Z Zídek; K Masek; F Sedivý
Journal:  Agents Actions       Date:  1984-01

10.  Modulation of lymphocyte activating factor activity (interleukin 1 like activity) and acute phase proteins in pertussis-induced air pouch inflammation by muramyl dipeptide.

Authors:  A D Sedgwick; R E Hooke; P Lees; S A May
Journal:  Agents Actions       Date:  1987-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.